Drew Provan

Summary

Affiliation: Queen Mary
Country: UK

Publications

  1. ncbi request reprint Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults
    Drew Provan
    St Bartolomew s and The Royal London School of Medicine and Dentistry, London, UK
    Br J Haematol 118:933-44. 2002
  2. ncbi request reprint Idiopathic thrombocytopenic purpura in adults
    Drew Provan
    Department of Haematology, Barts and the London School of Medicine and Dentistry, Whitechapel Road, London E1 1BB, U K
    J Pediatr Hematol Oncol 25:S34-8. 2003
  3. doi request reprint International consensus report on the investigation and management of primary immune thrombocytopenia
    Drew Provan
    Department of Haematology, Barts and the London School of Medicine and Dentistry, London, United Kingdom
    Blood 115:168-86. 2010
  4. ncbi request reprint Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura
    Drew Provan
    Bart s and The London, Queen Mary s School of Medicine and Dentistry, London, United Kingdom
    Am J Hematol 81:19-25. 2006
  5. ncbi request reprint Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults
    Drew Provan
    Department of Haematology, Bart s and The London, Queen Mary s School of Medicine and Dentistry, Whitechapel, London, UK
    Haematologica 92:1695-8. 2007
  6. ncbi request reprint Alpha-galactosylceramide-driven expansion of human natural killer T cells is inhibited by prednisolone treatment
    Ulrika Johansson
    Department of Haematology, Barts and The London, Queen Mary School of Medicine and Dentistry, London, UK
    Br J Haematol 125:400-4. 2004
  7. doi request reprint Immune thrombocytopenia -- what are the new treatment options?
    Simon Hallam
    Queen Mary University of London, Bart s and The London School of Medicine and Dentistry, Department of Haematology, Whitechapel, London El 2ES, UK
    Expert Opin Biol Ther 13:1173-85. 2013

Detail Information

Publications7

  1. ncbi request reprint Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults
    Drew Provan
    St Bartolomew s and The Royal London School of Medicine and Dentistry, London, UK
    Br J Haematol 118:933-44. 2002
  2. ncbi request reprint Idiopathic thrombocytopenic purpura in adults
    Drew Provan
    Department of Haematology, Barts and the London School of Medicine and Dentistry, Whitechapel Road, London E1 1BB, U K
    J Pediatr Hematol Oncol 25:S34-8. 2003
    ....
  3. doi request reprint International consensus report on the investigation and management of primary immune thrombocytopenia
    Drew Provan
    Department of Haematology, Barts and the London School of Medicine and Dentistry, London, United Kingdom
    Blood 115:168-86. 2010
    ..The inclusion of summary tables within this document, supported by information tables in the online appendices, is intended to aid in clinical decision making...
  4. ncbi request reprint Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura
    Drew Provan
    Bart s and The London, Queen Mary s School of Medicine and Dentistry, London, United Kingdom
    Am J Hematol 81:19-25. 2006
    ..The data suggests that response rates to MMF may be higher in patients who have had a shorter duration of their ITP...
  5. ncbi request reprint Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults
    Drew Provan
    Department of Haematology, Bart s and The London, Queen Mary s School of Medicine and Dentistry, Whitechapel, London, UK
    Haematologica 92:1695-8. 2007
    ..The immunotherapy had no effect in 1 patient with pure red cell aplasia or in 1 patient with autoimmune neutropenia. No infusion-related or delayed toxicities attributable to rituximab were experienced by any of the patients...
  6. ncbi request reprint Alpha-galactosylceramide-driven expansion of human natural killer T cells is inhibited by prednisolone treatment
    Ulrika Johansson
    Department of Haematology, Barts and The London, Queen Mary School of Medicine and Dentistry, London, UK
    Br J Haematol 125:400-4. 2004
    ..These results support a role for NKT cells in ITP and aid understanding of the immunosuppressive activities of prednisolone in autoimmune disease...
  7. doi request reprint Immune thrombocytopenia -- what are the new treatment options?
    Simon Hallam
    Queen Mary University of London, Bart s and The London School of Medicine and Dentistry, Department of Haematology, Whitechapel, London El 2ES, UK
    Expert Opin Biol Ther 13:1173-85. 2013
    ..The overall mortality rate for ITP is < 1%, and the morbidity and mortality associated with treatment can be worse than the disease...